id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-P-0624-0009,FDA,FDA-2010-P-0624,FDA/CDER to Cubist Pharmaceuticals - Petition Partial Approval and Denial,Other,PPAD-Petition Partial Approval and Denial,2011-06-06T04:00:00Z,2011,6,2011-06-06T04:00:00Z,,2013-08-11T03:15:12Z,,0,0,0900006480e3d74a
FDA-2010-P-0624-0007,FDA,FDA-2010-P-0624,"Exhibit 25 - ""FDA/CDER Letter to Cubist Pharmaceuticals, Inc., March 22, 2004"" -  [Cubist Pharmaceuticals, Inc. - Supplement] re FDA-2010-P-0624-0005",Supporting & Related Material,SUP-Supplement (Supporting and Related Material),2011-02-15T05:00:00Z,2011,2,,,2011-02-16T00:26:38Z,,0,0,0900006480bcd3d0
FDA-2010-P-0624-0006,FDA,FDA-2010-P-0624,"Exhibit 24 - ""Microbiology Comments: Dapto Labeling Supplement (NDA21-572/S-007)"" -  [Cubist Pharmaceuticals, Inc. - Supplement] re FDA-2010-P-0624-0005",Supporting & Related Material,SUP-Supplement (Supporting and Related Material),2011-02-15T05:00:00Z,2011,2,,,2011-02-16T00:23:48Z,,0,0,0900006480bcd3ce
FDA-2010-P-0624-0008,FDA,FDA-2010-P-0624,"Exhibit 26 - ""Cubist Letter to FDA/CDER, September 14, 2000 re Change in Manufacturer Procedure for Daptomycin API"" - [Cubist Pharmaceuticals, Inc. - Supplement] re FDA-2010-P-0624-0005",Supporting & Related Material,SUP-Supplement (Supporting and Related Material),2011-02-15T05:00:00Z,2011,2,,,2011-02-16T00:31:19Z,,0,0,0900006480bcda9d